New Aspects in Physiological Antitumor Substances: Experimental and Clinical Studies with Xenogenic Peptides and Proteins |
Contents
Therapeutic Integration of Xenogenic Proteins and Peptides | 17 |
Voelter W Friedl Ch Kalbacher H Tübingen Munder P G Freiburg | 33 |
The Inhibition of Tumor Proliferation by Specific Factors | 59 |
Copyright | |
7 other sections not shown
Common terms and phrases
6-mercaptopurine acid activity adriamycin animals antigen Aspects in Physiological biological blood Calc cancer carcinoma cell cultures cell membrane chemotherapy circadian clinical colony CONRAY cytostatic cytotoxic demonstrated diploid disease displayed DNA-synthesis dose DR DANGEL STUTTGART E-Sol effect extracts factors flow cytometry fluorescence foetal growth hemoderivative histograms human hypernephroma immune immunoglobulin immunological immunotherapy increase incubation inhibition inhibitor injection Karger labeled Letnansky leukemia levamisole liver lung lymph-node lymphocytes malignant melanoma metastases methods mice mitomycin mmol monoclonal antibodies natn NeyThymun NeyTumorin NeyTumorin®-Sol non-specific normal cells ORAL CONRAY organs parameters parasympathicotonic particles patients peptides phase phenotype Physiological Antitumor Substances placenta preparations proliferation protein reaction situation regression sarcoma scatter serum showed SOMATOM specific stem cells stimulation studies sympathicotonic synthesis T-cells T-lymphocytes therapeutic therapy Theurer thymosin thymus tion tissue treatment tumor cells Tumorin vitro vivo Wish cell xenogenic xenogenic peptides µg/ml